checkAd

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,002,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company.

The gross proceeds from the offering are expected to be approximately $300.4 million, before underwriting discounts and commissions and offering expenses payable by the Company, and without giving effect to any exercise by the underwriters of their option to purchase additional shares.

Morgan Stanley, BofA Securities, Cowen and Stifel are acting as the book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering. The offering is expected to close on or about December 5, 2022, subject to customary closing conditions.

The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of an automatically effective registration statement. A final prospectus supplement related to the offering will be filed with the Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, by contacting: Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department, by telephone: 1-866-718-1649, or by email at prospectus@morganstanley.com; BofA Securities, 200 North College Street, 3rd floor, Charlotte, NC (28255-0001), Attn: Prospectus Department, by telephone: 1-800-294-1322, or by email at dg.prospectus_requests@bofa.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: 1-833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone: 1-415-364-2720, or by email at syndprospectus@stifel.com.

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  104   |   |   

Schreibe Deinen Kommentar

Disclaimer

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and …

Nachrichten des Autors

112 Leser
104 Leser
104 Leser
104 Leser
104 Leser
100 Leser
100 Leser
824 Leser
708 Leser
616 Leser
588 Leser
468 Leser
420 Leser
420 Leser
404 Leser
400 Leser
396 Leser
3236 Leser
2100 Leser
1772 Leser
1604 Leser
1604 Leser
1180 Leser
1004 Leser
884 Leser
848 Leser
844 Leser
7528 Leser
3236 Leser
3085 Leser
2934 Leser
2501 Leser
2460 Leser
2370 Leser
2169 Leser
2106 Leser
2100 Leser